Aktuelle Ringversuche

Getestete Parameter:

Bakteriologie (5 Proben)

Gramfärbung, Anzüchtung, Identifizierung und Empfindlichkeitsprüfung von Bakterien

Getestete Parameter:

Immunhämatologie 03 - Thrombozytenimmunologie:

Nachweis thrombozytärer Antikörper

Getestete Parameter:

Ringversuch für Schilddrüsenantikörper im Serum

Anti-TG(TAK), Anti-TPO(MAK), Anti-TSH-Rez(TRAK)

Getestete Parameter:

HbA1c

Getestete Parameter:

Ringversuch für Molekularbiologie, Gruppe 1:

FV-Leiden (F5, NM_000130..., FII g20210a (F2, NM_0005..., MTHFR C677T (MTHFR, NM_0..., MTHFR A1298C (MTHFR, NM_..., PAI-I 4G5G (SERPINE1, NM...,   AAT-PI*S (SERPINA1, NM_0..., AAT-PI*Z (SERPINA1, NM_0..., AAT, Alpha-1-Antitrypsin..., ApoE2 (APOE, NM_000041.4..., ApoE4 (APOE, NM_000041.4..., ApoE, Apolipoprotein E –..., ApoB100 (APOB, NM_000384…, HFE H63D (HFE, NM_000410..., HFE S65C (HFE, NM_000410..., HFE C282Y (HFE, NM_00041..., LCT c-13910t (LCT, NM_00...,  AT3 Cambridge Typ I/II (... CYP3A5*3 (CYP3A5, NM_000..

Getestete Parameter:

Ringversuch für Molekularbiologie, Gruppe 2:

TPMT*2 (TPMT, NM_000367...., TPMT*3B (TPMT, NM_000367..., TPMT*3C (TPMT, NM_000367..., Thiopurine S-methyltrans..., CYP2C8*3 (CYP2C8, NM_000..., CYP2C9*2 (CYP2C9, NM_000..., CYP2C9*3 (CYP2C9, NM_000..., CYP2C9 - 2C9 - Genotypis..., UGT1A1*28 (UGT1A1, NM_00..., DPYD*2A (DPYD, NM_000110..., DPYD*13 (DPYD, NM_000110..., DPYD p.D949V (DPYD, NM_0..., DPYD c.1236G>A (DPYD, NM..., DPD activity score acc. ..., DPD activity score acc. ..., CYP2D6*2-296 (CYP2D6*2, ..., CYP2D6*3 (CYP2D6*3, NM_0..., CYP2D6*4 (CYP2D6*4, NM_0..., CYP2D6*6 (CYP2D6*6, NM_0..., CYP2D6*7 (CYP2D6*7, NM_0..., CYP2D6*8 (CYP2D6*8, NM_0..., CYP2D6*9 (CYP2D6*9, NM_0..., CYP2D6*10 (CYP2D6*10, NM..., CYP2D6*35 (CYP2D6*35, NM..., CYP2D6*41 (CYP2D6*41, NM..., CYP2D6*5 (CYP2D6, Deleti..., CYP2D6*xN (CYP2D6, Dupli..., CYP2C19*2 (CYP2C19, NM_0..., CYP2C19*3 (CYP2C19, NM_0..., CYP2C19*17 (CYP2C19, NM_..., CYP2C19 Genotypisierung HLA B*57:01 (HLA-B, NM_0..., CYP2B6*4 (CYP2B6, NM_000..., CYP2B6*9 (CYP2B6, NM_000..., CYP2B6*6 (NM_000767.5:c...., CYP3A4*22 (CYP3A4, NM_01..., Cyp2D6 Genotyp

Getestete Parameter:

Ringversuch zur quantitativen Bestimmung von Antidepressiva in Serum:

Bupropion, Hydroxybupropion, Milnacipran, Moclobemid, Methylphenidat, Ritalinsäure, Atmoxetin, Tranylcypromin, Vortioxetin

Getestete Parameter:

Doxepin, Nordoxepin, Amitriptylin, Nortriptylin, Trimipramin, Opipramol, Imipramin, Desipramin, Clomipramin, Norclomipramin, Maprotilin

Getestete Parameter:

Ciclosporin, Tacrolimus, Sirolimus, Everolimus

Getestete Parameter:

Ringversuch für die systematische toxikologische Analyse (STA)

Getestete Parameter:

Ringversuch für spezielle Autoantikörper:

ANA (antinukl. AK), ENA-Screening-Test, U1-snRNP, Sm, SS-A (gesamt), SS-A (Ro52), SS-A (Ro60), SS-B, Jo1, SCL-70, CENP B, Histone, ds-DNS AK, ANCA, MPO, PR3, GBM, AMA, AMA quant. PDH-Komplex, SMA, LKM-1 Cardiolipin IgG, Cardiolipin IgM, beta2-Glycoprot. IgG, beta2-Glycoprot. IgM, Endomysium IgA, Transglutaminase IgG, Transglutaminase IgA, Gliadin DGP IgG, Gliadin DGP IgA

Getestete Parameter:

Digitoxin (R B1a), Vancomycin (R: B1a), Amikacin, Gentamicin, Methotrexat, Tobramycin

Getestete Parameter:

Autoimmunerkrankungen 13 - Antiphospholipidsyndrom:

anti-Cardiolipin (IgG), anti-Cardiolipin (IgM), anti-Cardiolipin (IgA), anti-ß2-GLykoprotein (IgG), anti-ß2-Glykoprotein (IgM)

Getestete Parameter:

Autoimmunerkrankungen 07 - Autoimmune Endokrinopathien

anti-Nebennierenrinde - IIFT

Getestete Parameter:

Autoimmunerkrankungen 06 - Diabetes mellitus:

anti-Inselzellen - IIFT, anti-lnsulin (IAA) - semiquantitativ, anti-Glutamat-decarboxylase (GAD) - semiquantitativ, anti-Tyrosinphosphatase (IA2) - semiquantitativ,  anti-Zinktransporter (ZnT8A) - semiquantitativ